Adage Capital Partners GP L.L.C. Takes $7.26 Million Position in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Adage Capital Partners GP L.L.C. bought a new position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 157,618 shares of the company's stock, valued at approximately $7,261,000. Adage Capital Partners GP L.L.C. owned about 0.56% of Establishment Labs at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ESTA. Barclays PLC increased its stake in shares of Establishment Labs by 9,643.3% during the 3rd quarter. Barclays PLC now owns 31,471 shares of the company's stock worth $1,362,000 after purchasing an additional 31,148 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of Establishment Labs during the 4th quarter worth about $12,898,000. Raymond James Financial Inc. acquired a new position in shares of Establishment Labs during the 4th quarter worth about $5,494,000. Swiss National Bank increased its stake in shares of Establishment Labs by 2.7% during the 4th quarter. Swiss National Bank now owns 38,500 shares of the company's stock worth $1,774,000 after purchasing an additional 1,000 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Establishment Labs during the 4th quarter worth about $161,000. 72.91% of the stock is owned by institutional investors.

Establishment Labs Stock Down 1.3 %

Shares of ESTA opened at $29.57 on Tuesday. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62. The firm has a market cap of $852.98 million, a P/E ratio of -11.46 and a beta of 0.77. Establishment Labs Holdings Inc. has a 52 week low of $26.56 and a 52 week high of $60.12. The firm's 50-day simple moving average is $35.96 and its 200 day simple moving average is $39.14.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.34). The business had revenue of $44.51 million during the quarter, compared to the consensus estimate of $44.45 million. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. On average, analysts forecast that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Wall Street Analyst Weigh In

ESTA has been the topic of several recent analyst reports. Needham & Company LLC initiated coverage on shares of Establishment Labs in a research note on Monday, April 14th. They set a "hold" rating on the stock. Stephens restated an "overweight" rating and set a $52.00 price objective on shares of Establishment Labs in a research note on Thursday, March 6th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $57.40.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.